Cytotoxic activity evaluation, DNA and thioredoxin reductase enzyme interaction studies of heterobimetallic Pt(II)-Au(I) complexes as potential anticancer agents

Document Type : Original Article


1 Medicinal chemistry department, school of pharmacy, Jundishapur university of Medical Sciences, Ahvaz, Iran

2 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran


Background and Aim: Platinum-based chemotherapy drugs like cisplatin are widely used in the treatment of cancer. However, because of its high side effects, the use of these compounds is limited. All of today's efforts is to design new platinum drugs, as well as hybrid of gold and platinum, which have a similar profile with cisplatin but have less side effects and wide spectrum on different cancer types.
Material and Method: In this study, the cytotoxic activity of heterobimetallic Pt(II)-Au(I) complexes on the cancer cell lines such as cervix (Hela), colon (SW1116), breast (MDA-MB-231) as well as normal breast (MCF-12A) cell line was evaluated using MTT method. Molecular docking studies of these compounds with DNA and thioredoxin reductase (TrxR), as targets for platinum and gold compounds, were conducted using AutoDock 4.2 software. Using the comet assay, genotoxicity of the best cytotoxic compound was also evaluated.
Result: In evaluating the cytotoxic activity, 1b and 2b complexes exhibited greater cytotoxicity than cisplatin. All compounds exhibited lower toxicity than cisplatin on normal breast cell line (MCF-12A). The interaction of complexes with DNA and TrxR using molecular docking was also investigated and their binding mode and binding site were determined. The genotoxicity effect of these compounds was also confirmed by the comet assay.
Conclusion: These complexes with further biological studies, have the ability to play a more effective role in the treatment of cancer.


1-Wang X, Guo Z. Targeting and delivery of platinum-based anticancer drugs. Chemical Society Reviews. 2013;42(1):202-24.
2-Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature reviews Cancer. 2007;7(8):573-84.
3-Zou T, Lok CN, Wan PK, Zhang ZF, Fung SK, Che CM. Anticancer metal-N-heterocyclic carbene complexes of gold, platinum and palladium. Current opinion in chemical biology. 2018;43:30-6.
4-Lazarevic T, Rilak A, Bugarcic ZD. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. European journal of medicinal chemistry. 2017;142:8-31.
5-Liu D, He C, Wang AZ, Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine. 2013;8:3309-19.
6-Lokich J. What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? Cancer investigation. 2001;19(7):756-60.
7-Monneret C, editor Platinum anticancer drugs. From serendipity to rational design. Annales pharmaceutiques françaises; 2011: Elsevier.
8-Zhang X, Selvaraju K, Saei AA, D'Arcy P, Zubarev RA, Arner ES, et al. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug. Biochimie. 2019;162:46-54.
9-Ott I. On the medicinal chemistry of gold complexes as anticancer drugs. Coordination Chemistry Reviews. 2009;253(11):1670-81.
10-Kozubík A, Vaculová A, Souček K, Vondráček J, Turánek J, Hofmanová J. Novel anticancer platinum (IV) complexes with adamantylamine: their efficiency and innovative chemotherapy strategies modifying lipid metabolism. Metal-based drugs. 2008;2008.
11-Shahsavari HR, Giménez N, Lalinde E, Moreno MT, Fereidoonnezhad M, Babadi Aghakhanpour R, et al. Heterobimetallic PtII-AuI Complexes Comprising Unsymmetrical 1,1-Bis(diphenylphosphanyl)methane Bridges: Synthesis, Photophysical, and Cytotoxic Studies. European Journal of Inorganic Chemistry. 2019;2019(10):1360-73.
12-Fereidoonnezhad M, Ramezani Z, Nikravesh M, Zangeneh J, Haghighi MG, Faghih Z, et al. Cycloplatinated (II) complexes bearing an O, S-heterocyclic ligand: search for anticancer drugs. New Journal of Chemistry. 2018;42(9):7177-87.
13- Fereidoonnezhad M, Shahsavari HR, Abedanzadeh S, Behchenari B, Hossein-Abadi M, Faghih Z, et al. Cycloplatinated(ii) complexes bearing 1,1′-bis(diphenylphosphino)ferrocene ligand: biological evaluation and molecular docking studies. New Journal of Chemistry. 2018;42(4):2385-92.
14- Fereidoonnezhad M, Niazi M, Shahmohammadi Beni M, Mohammadi S, Faghih Z, Faghih Z, et al. Synthesis, biological evaluation, and molecular docking studies on the DNA binding interactions of platinum (II) rollover complexes containing phosphorus donor ligands. ChemMedChem. 2017;12(6):456-65.
15-Fereidoonnezhad M, Kaboudin B, Mirzaee T, Babadi Aghakhanpour R, Golbon Haghighi M, Faghih Z, et al. Cyclometalated Platinum (II) Complexes Bearing Bidentate O, O′-Di (alkyl) dithiophosphate Ligands: Photoluminescence and Cytotoxic Properties. Organometallics. 2017;36(9):1707-17.
16-Blechinger J, Varzackii OA, Kovalska V, Zelinskii GE, Voloshin YZ, Kinski E, et al. Cytotoxicity of electrophilic iron (II)–clathrochelates in human promyelocytic leukemia cell line. Bioorganic & medicinal chemistry letters. 2016;26(2):626-9.
17-Fereidoonnezhad M, Niazi M, Ahmadipour Z, Mirzaee T, Faghih Z, Faghih Z, et al. Cyclometalated Platinum (II) Complexes Comprising 2‐(Diphenylphosphino) pyridine and Various Thiolate Ligands: Synthesis, Spectroscopic Characterization, and Biological Activity. European Journal of Inorganic Chemistry. 2017;2017(15):2247-54.
18-Fereidoonnezhad M, Mostoufi A, Zali S, Eskandari M, Afshar D, Aliyan F. Molecular Docking and PLIF Studies of Novel Tacrine-Naphtoquinone Hybrids Based on Multi-Target-Directed Ligand Approach for Alzheimer’s Disease. Jundishapur Journal of Natural Pharmaceutical Products. 2018;13(2).
19-Bai X, Yang Z, Zhu M, Dong B, Zhou L, Zhang G, et al. Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2− ligand: Structure− activity studies and biological evaluation. European journal of medicinal chemistry. 2017;137:30-44.
20-Alzheimer’s A. 2015 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2015;11(3):332.
21-Ray GB, Cook JW. Molecular modeling of heme proteins using MOE: Bio‐inorganic and structure‐function activity for undergraduates* S. Biochemistry and Molecular Biology Education. 2005;33(3):194-201.
22-Cetraz M, Sen V, Schoch S, Streule K, Golubev V, Hartwig A, et al. Platinum (IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells. Archives of toxicology. 2017;91(2):785-97.
23-Pu X, Wang Z, Klaunig JEJCpit. Alkaline comet assay for assessing DNA damage in individual cells. 2015;65(1):3.12. 1-3.. 1.
24-Zare S, Fereidoonnezhad M, Afshar D, Ramezani Z. A comparative QSAR analysis and molecular docking studies of phenyl piperidine derivatives as potent dual NK1R antagonists/serotonin transporter (SERT) inhibitors. Computational biology and chemistry. 2017;67:22-37.
25-Samouei H, Rashidi M, Heinemann FW. A cyclometalated diplatinum complex containing 1, 1′-bis (diphenylphosphino) ferrocene as spacer ligand: Antitumor study. Journal of Organometallic Chemistry. 2011;696(23):3764-71.
26-Ghani NTA, Mansour AM. Novel palladium (II) and platinum (II) complexes with 1H-benzimidazol-2-ylmethyl-N-(4-bromo-phenyl)-amine: Structural studies and anticancer activity. European journal of medicinal chemistry. 2012;47:399-411.
27-Lyu A, Qin X, Fang L, Gou S. Synthesis, cytotoxicity, and interaction with DNA of platinum (II) complexes of (1 R, 2 R)-N1-2-amyl-1, 2-diaminocyclohexane. Journal of Coordination Chemistry. 2016;69(10):1653-62.
28- Jomaa MY, Altaf M, Ahmad S, Bhatia G, Singh J, Altuwaijri S, et al. Synthesis, spectroscopic characterization and in vitro anticancer activity of new platinum (II) complexes with some thione ligands in the presence of triethylphosphine. Biometals. 2017;30(5):787-95.
29-Fereidoonnezhad M, Shahsavari HR, Lotfi E, Babaghasabha M, Fakhri M, Faghih Z, et al. (Benzyl isocyanide)gold(I) pyrimidine-2-thiolate complex: Synthesis and biological activity. Applied Organometallic Chemistry. 2018;32(3):e4200-n/a.